Akari Therapeutics Plc/ US00972G1085 /
| 6/29/2022 9:59:50 PM | Chg. - | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 0.95USD | - | 300 Turnover: 289 |
-Bid Size: - | -Ask Size: - | 0.99 | 0.95 |
GlobeNewswire
3/21
Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and ...
GlobeNewswire
3/2
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
GlobeNewswire
2/28
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Cl...
GlobeNewswire
2/24
Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer
GlobeNewswire
1/26
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbation...
GlobeNewswire
1/19
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Stu...
GlobeNewswire
12/3/2021
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progr...
GlobeNewswire
12/1/2021
Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerb...
GlobeNewswire
10/26/2021
Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit
GlobeNewswire
10/25/2021
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
GlobeNewswire
9/22/2021
Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
GlobeNewswire
9/22/2021
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Prog...
GlobeNewswire
9/10/2021
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid ...
GlobeNewswire
9/7/2021
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
GlobeNewswire
6/29/2021
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
GlobeNewswire
4/28/2021
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pe...
GlobeNewswire
4/22/2021
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase II...
GlobeNewswire
4/21/2021
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress